The antihypertensive and cardioprotective effects of (-)-MJ-451, an ATP-sensitive K+ channel opener

Yen Mei Lee, Mao Hsiung Yen, Yen Yen Peng, Jeon Rong Sheu, Yao Chang Chen, Ming Jyh Chang, Chen Yu Cheng

研究成果: 雜誌貢獻文章同行評審

8 引文 斯高帕斯(Scopus)


ATP-sensitive K+ (K(ATP)) channel openers have been shown to be a potential class of therapeutic agents for the control of cardiovascular diseases, including angina, arrhythmias, and hypertension. In this study, the pharmacological activity of 6-cyano-3S,4R-dihydro-2,2-dimethyl-2H-3-hydroxy-4-[5S-(1-hydroxymethyl)-2-oxo-1-pyrrolidinyl]-1-benzopyran ((-)-MJ-451), a synthetic K(ATP) opener, was evaluated in anesthetized rat models and in isolated rat thoracic rings. Results demonstrated that intravascular injection of (-)-MJ-451 (0.02, 0.05 and 0.1 mg/kg) produced an immediate, dose-related reduction in mean arterial blood pressure in anesthetized spontaneously hypertensive rats (SHR), which persisted for more than 3 h and was not accompanied by reflex tachycardia. The hemodynamic changes were completely abolished by pretreatment with glibenclamide (4 mg/kg, i.v. bolus), a selective K(ATP) channel blocker. In isolated thoracic aorta, (-)-MJ-451 (10 nM-3 μM) produced a concentration-dependent vasodilator effect on the phenylephrine (0.3 μM)-induced vasoconstriction. Moreover, (-)-MJ-451 relaxed the thoracic aorta contracted by low (5, 20 and 30 mM), but not high (40 and 60 mM) concentrations of extracellular potassium. In addition, (-)-MJ-451 showed cardioprotective effects in the rat model of 45-min left coronary artery occlusion followed by 1-h reperfusion. In myocardial ischemia, pretreatment with (-)-MJ-451 (2, 5 and 10 μg/kg, i.v. bolus) significantly reduced the incidence of ventricular fibrillation and the mortality, also reducing the total number of ventricular premature contractions, total duration of ventricular tachycardia and ventricular fibrillation. A significant reduction in infarct size was noted in three (-)-MJ-451 (2, 5 and 10 μg/kg)-treated groups. Also, the cardioprotective effects of (-)-MJ-451 were virtually abolished by pretreating the rats with glibenclamide (4 mg/kg, i.v. bolus). In conclusion, (-)-MJ-451, through opening the K(ATP) channel, exerted antihypertensive and cardioprotective effects. Therefore, it is suggested that (-)-MJ-451 has potential in the treatment of hypertension or acute myocardial infarction. Copyright (C) 2000 Elsevier Science B.V.

頁(從 - 到)151-160
期刊European Journal of Pharmacology
出版狀態已發佈 - 5月 26 2000

ASJC Scopus subject areas

  • 細胞與分子神經科學
  • 藥理


深入研究「The antihypertensive and cardioprotective effects of (-)-MJ-451, an ATP-sensitive K+ channel opener」主題。共同形成了獨特的指紋。